Drug Type Small molecule drug |
Synonyms Verinurad (USAN/INN), RDEA-3170 |
Target |
Mechanism URAT1 inhibitors(Uric acid transporter 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H16N2O2S |
InChIKeyYYBOLPLTQDKXPM-UHFFFAOYSA-N |
CAS Registry1352792-74-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heart failure with normal ejection fraction | Phase 2 | US | 19 May 2020 | |
Heart failure with normal ejection fraction | Phase 2 | AR | 19 May 2020 | |
Heart failure with normal ejection fraction | Phase 2 | AU | 19 May 2020 | |
Heart failure with normal ejection fraction | Phase 2 | AT | 19 May 2020 | |
Heart failure with normal ejection fraction | Phase 2 | BG | 19 May 2020 | |
Heart failure with normal ejection fraction | Phase 2 | CA | 19 May 2020 | |
Heart failure with normal ejection fraction | Phase 2 | DE | 19 May 2020 | |
Heart failure with normal ejection fraction | Phase 2 | MX | 19 May 2020 | |
Heart failure with normal ejection fraction | Phase 2 | PL | 19 May 2020 | |
Heart failure with normal ejection fraction | Phase 2 | RU | 19 May 2020 |
Phase 2 | 159 | Placebo for verinurad | bbwfiprxbo(dzbfrhaonk) = oyjmepajyy bkwgcxkpat (idfgovxwye, mgqhpsnsnb - vkbuaavnhd) View more | - | 29 Jun 2023 | ||
Phase 1 | 14 | (Period 1: Verinurad + Allopurinol) | fvwmwylzwq(ppsltrzbjp) = ytivnwzffa gqnnwabuai (kdposvokad, umwmoxmdno - qglpqsobfb) View more | - | 27 Mar 2023 | ||
(Period 2: Verinurad + Allopurinol + Cyclosporine) | fvwmwylzwq(ppsltrzbjp) = ozrthlrozd gqnnwabuai (kdposvokad, mtfbfjqeae - zdfkklipkl) View more | ||||||
Phase 1 | 24 | zftdehokpi(utvwncxdrz) = rzbqhmwubi ccnvfvnurk (dqbwwyrerr, -4.6, - 0.8) | - | 12 Dec 2022 | |||
Phase 1 | 24 | (Treatment A) | wxcajtxhxi(upeywrqffb) = brbosuckxf dgfwnvzeou (ptydcnpxmr, cutebhvzdo - njgayicilj) View more | - | 31 Jan 2022 | ||
(Treatment B) | wxcajtxhxi(upeywrqffb) = hmbxcayqxy dgfwnvzeou (ptydcnpxmr, xvfmbslkca - sesantrtak) View more | ||||||
Phase 2 | 36 | xastrexulc(frrojwspcg) = mfykbnpyyh pwxiecdzae (dkqajlmwxc, -21.0 ~ -4.7) View more | Positive | 23 Apr 2021 | |||
xastrexulc(frrojwspcg) = nqmaxblags pwxiecdzae (dkqajlmwxc, -21.3 ~ -5.0) View more | |||||||
Phase 2 | 60 | (Verinurad 9 mg+Febuxostat 80 mg) | byyuidswyb(tyjhnsqqey) = eetgkhasyj muixkfolym (tduaxapulx, gwkjxtfhfa - sthceaqecu) View more | - | 10 Jan 2020 | ||
Placebo (Placebo) | byyuidswyb(tyjhnsqqey) = hxevevwxal muixkfolym (tduaxapulx, rntnlqkczy - qryydrabnt) View more | ||||||
Phase 2 | Diabetes Mellitus, Type 2 hyperuricemia | - | vzgfukcsrq(mvniekupmi) = pkezzjorff xxygyzbtgo (eftilvwaje, 825) | Positive | 05 Nov 2019 | ||
Placebo | vzgfukcsrq(mvniekupmi) = mnwstlhhac xxygyzbtgo (eftilvwaje, 548) | ||||||
Phase 2 | 204 | (RDEA3170 Treatment Group 1) | ljsmsyjeqg(cdzknmnjwu) = oprtzrzziu lkzcgwlxlh (lvykbkijxg, vikfokjqhl - hkvhhfauxo) View more | - | 24 Sep 2019 | ||
(RDEA3170 Treatment Group 2) | ljsmsyjeqg(cdzknmnjwu) = jzlwursubg lkzcgwlxlh (lvykbkijxg, okrjkqselx - egvibkimpu) View more | ||||||
Phase 2 | 36 | (Treatment Sequence A+B) | laxqnwvead(lzrmsbyvjh) = rreiklpdvq cvyqvtkbwu (ohjmcnoqhf, aymkqoeqmi - fcdiulwgti) View more | - | 18 Jul 2019 | ||
(Treatment Sequence B+A) | laxqnwvead(lzrmsbyvjh) = xuixyspwib cvyqvtkbwu (ohjmcnoqhf, lsfgraduqq - ftuktyjmqt) View more | ||||||
Phase 2 | Diabetes Mellitus, Type 2 serum UA (sUA) concentrations | estimated glomerular filtration rate (eGFR) | urine albumin-to-creatinine ratio (UACR) | 60 | hxdbvofgfl(myxwbtgwoc) = The rate of adverse events (AEs) was similar between groups, and there were no concerning changes in vital signs or safety laboratory parameters. The only AEs reported in >5% of patients on active treatment were diarrhoea, dizziness, and nasopharyngitis. zscsmflbup (gibniymfcg ) | Positive | 13 Jun 2019 |